Monte Rosa Therapeutics: Q3 Earnings Snapshot
Monte Rosa Therapeutics: Q3 Earnings Snapshot
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics: Q2 Earnings Snapshot
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Analysts have high hopes for these three innovation companies in 2024.
Pre-Market Brief: Stocks Climb As Investors Await FOMC Minutes
March S&P 500 futures (ESH23) are trending up +1.12% this morning after three major U.S. benchmark indices closed lower on 2022’s last trading day as market participants braced for the new year with...
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors...
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue...